Benazepril (Fortekor, Lotensin)

Benazepril is an angiotensin-converting enzyme inhibitor, commonly known as an ACE inhibitor, that plays a vital role in the management of cardiovascular disease and chronic kidney disease in dogs. This medication is marketed under various brand names including Fortekor, which is specifically approved for veterinary use, and Lotensin, a human formulation sometimes prescribed off-label for dogs. ACE inhibitors have become cornerstone medications in veterinary cardiology and nephrology, helping countless dogs maintain quality of life while living with heart disease or kidney dysfunction. Benazepril's well-established efficacy and safety profile have made it one of the most commonly prescribed cardiac medications in veterinary medicine.

The mechanism of action of benazepril involves blocking the angiotensin-converting enzyme, which plays a central role in the renin-angiotensin-aldosterone system that regulates blood pressure and fluid balance. When ACE is inhibited, the conversion of angiotensin I to angiotensin II is blocked, preventing the powerful vasoconstriction and fluid retention that angiotensin II normally causes. This results in dilation of blood vessels, reduced blood pressure, decreased workload on the heart, and improved cardiac output. Additionally, ACE inhibition reduces aldosterone production, which helps decrease sodium and water retention. These combined effects help relieve the symptoms of heart failure and slow disease progression.

Benazepril is available in tablet form in various strengths to accommodate dogs of different sizes. The medication is typically administered once or twice daily depending on the specific condition being treated and the veterinarian's recommendations. Fortekor tablets are specifically formulated for veterinary patients and come in strengths designed for easy dosing in dogs ranging from small breeds to giant breeds. When human formulations are used, veterinarians calculate appropriate doses based on the dog's weight and condition. The tablets can generally be given with or without food, though consistent administration with meals may improve compliance.

Veterinary supervision is essential when using benazepril, as the medication requires careful monitoring and dose adjustments based on the individual dog's response and disease progression. Before starting treatment, veterinarians typically perform baseline blood work to assess kidney function and electrolyte levels, as these can be affected by ACE inhibitor therapy. Regular monitoring throughout treatment helps ensure the medication is providing benefit without causing adverse effects. Dogs with heart disease or kidney disease require ongoing veterinary care, and benazepril is typically one component of a comprehensive management plan that may include other medications, dietary modifications, and lifestyle adjustments tailored to each patient's needs.

Benazepril is primarily indicated for the management of congestive heart failure in dogs, helping to reduce the clinical signs of heart disease and improve quality of life for affected patients. Heart failure occurs when the heart can no longer pump blood efficiently enough to meet the body's needs, leading to fluid accumulation in the lungs, abdomen, or both. By reducing the workload on the heart through vasodilation and decreasing fluid retention, benazepril helps alleviate symptoms such as coughing, exercise intolerance, difficulty breathing, and fatigue. The medication is often used in combination with other cardiac drugs such as diuretics and pimobendan to achieve optimal heart failure management.

Valvular heart disease, particularly mitral valve disease, is the most common form of heart disease in dogs and represents a major indication for benazepril therapy. As the valve deteriorates and allows blood to leak backward with each heartbeat, the heart must work harder to maintain circulation. Over time, this leads to heart enlargement and eventually heart failure. ACE inhibitors help by reducing the resistance against which the heart must pump and by modifying the neurohormonal activation that contributes to disease progression. Starting benazepril at appropriate stages of valvular disease can help slow the progression to heart failure and extend both quantity and quality of life.

Dilated cardiomyopathy, a condition in which the heart muscle becomes weakened and the heart chambers enlarge, is another important indication for benazepril in dogs. Large and giant breed dogs are predisposed to this condition, which can progress to congestive heart failure. ACE inhibitors are typically part of the standard treatment protocol for dilated cardiomyopathy, often combined with other medications that support heart function. The reduction in afterload provided by benazepril helps the weakened heart pump more effectively.

Chronic kidney disease is a significant indication for benazepril in dogs, as ACE inhibitors provide renal protective effects by reducing intraglomerular pressure and proteinuria. When the kidneys are damaged, the remaining nephrons often experience increased pressure as they attempt to compensate, which can accelerate further kidney damage. By dilating the efferent arterioles of the glomerulus, benazepril reduces this pressure and helps preserve remaining kidney function. Additionally, ACE inhibitors reduce protein loss in the urine, which is both a marker of kidney damage and a contributor to disease progression. Benazepril is often prescribed for dogs with proteinuric kidney disease even before overt clinical signs develop.

Systemic hypertension, or high blood pressure, in dogs may be treated with benazepril either as monotherapy or in combination with other antihypertensive agents. While hypertension in dogs is often secondary to underlying conditions such as kidney disease or hormonal disorders, controlling blood pressure is essential to prevent target organ damage affecting the eyes, kidneys, heart, and brain. ACE inhibitors effectively lower blood pressure through vasodilation and are well-suited for dogs with concurrent kidney disease or heart failure.

The dosing protocol for benazepril in dogs is weight-based, with veterinarians determining the appropriate dose and frequency based on the individual patient's condition, size, and overall health status. Typical starting doses range from 0.25 to 0.5 mg per kilogram of body weight, administered once or twice daily depending on the indication. For heart failure, twice-daily dosing is often preferred to maintain more consistent drug levels, while once-daily dosing may be appropriate for some cases of kidney disease or as maintenance therapy. The veterinarian tailors the dosing regimen to each patient's specific needs and may adjust doses based on response and tolerance.

Fortekor, the veterinary-approved benazepril product, is available in multiple tablet strengths including 2.5 mg, 5 mg, and 20 mg formulations to facilitate accurate dosing across the wide range of dog sizes. Small dogs may receive a portion of a lower-strength tablet, while large and giant breeds may require higher-strength tablets or combinations. When human formulations such as Lotensin are prescribed, similar weight-based calculations are applied, though tablet strengths may differ. Accurate weight measurement at the veterinary clinic ensures proper dosing, as both underdosing and overdosing can be problematic with ACE inhibitors.

Treatment with benazepril is typically long-term or lifelong for dogs with chronic heart disease or kidney disease, as these conditions are generally progressive and require ongoing management. The medication helps control symptoms and slow disease progression but does not cure the underlying condition. Dogs may remain on benazepril therapy for months to years, with regular veterinary monitoring to assess treatment effectiveness and adjust dosing as the disease evolves. Stopping benazepril abruptly is not recommended without veterinary guidance, as this can lead to worsening of the underlying condition.

Benazepril tablets can generally be administered with or without food, though giving the medication with meals may improve absorption and reduce the possibility of gastrointestinal upset. Establishing a consistent routine for medication administration helps ensure compliance and maintains steady drug levels. Some dogs readily accept tablets directly, while others may require hiding the medication in a small amount of food or a pill pocket. Tablets should not be crushed unless specifically directed by the veterinarian, as this may affect absorption characteristics.

If a dose of benazepril is missed, it should be given as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. Doubling up on doses is not recommended, as this increases the risk of hypotension and other adverse effects. Pet owners should maintain accurate records of medication administration and notify the veterinarian if multiple doses are missed, as this may affect disease management and require evaluation.

Before starting benazepril therapy, baseline blood work including kidney function tests and electrolytes is typically performed to establish reference values. Follow-up blood work is generally recommended within one to two weeks of starting treatment to ensure the kidneys are tolerating the medication well and that potassium levels remain normal. Ongoing monitoring at intervals determined by the veterinarian helps track disease progression and medication effects throughout the course of treatment.

Benazepril is generally well tolerated by most dogs when administered at appropriate doses under veterinary supervision. The medication has an established safety profile developed through extensive clinical use in veterinary medicine. Side effects, when they occur, are typically mild and often resolve with dose adjustment or supportive care. However, pet owners should be aware of potential adverse reactions and know when veterinary consultation is advisable to ensure continued safe treatment.

The most commonly observed side effects of benazepril relate to its blood pressure-lowering effects and may include weakness, lethargy, or decreased activity. These signs may be more pronounced when treatment is first started or after dose increases, as the body adjusts to lower blood pressure. Gastrointestinal effects such as decreased appetite, vomiting, or diarrhea occur in some dogs but are generally mild and transient. Some dogs may drink and urinate more frequently, which can be related to the medication's effects on fluid balance or may reflect underlying disease progression.

Moderate side effects requiring veterinary attention include signs of hypotension such as persistent weakness, fainting or collapse, or sudden reluctance to exercise or move normally. While these effects are uncommon at appropriate doses, they may indicate the dose is too high for the individual patient or that the dog's condition has changed in a way that affects medication tolerance. Changes in urination patterns, including significantly increased or decreased urine output, warrant veterinary evaluation. Persistent gastrointestinal symptoms or significant appetite loss should be reported, as these may affect medication absorption and overall nutritional status.

Serious adverse reactions to benazepril are uncommon but require immediate veterinary attention. Acute kidney injury can occur in some patients, particularly those with pre-existing significant kidney disease or those who become dehydrated. Signs may include dramatically decreased urination, vomiting, severe lethargy, or loss of appetite. Elevated potassium levels (hyperkalemia) can occur due to aldosterone suppression and may cause muscle weakness, cardiac arrhythmias, or collapse. Severe hypotension with collapse or inability to stand requires emergency care. Allergic reactions, while rare, may manifest as facial swelling, hives, or difficulty breathing.

Certain dogs may be at higher risk for adverse effects from benazepril, including those with severe kidney disease, significant dehydration, concurrent use of other blood pressure-lowering medications, or those receiving potassium supplements or potassium-sparing diuretics. Regular monitoring through blood work helps detect early changes in kidney function or electrolytes before clinical signs develop. Pet owners should inform the veterinarian immediately if their dog shows signs of illness during treatment, as dose adjustments or additional interventions may be needed.

Benazepril should not be administered to dogs with known hypersensitivity or previous allergic reactions to benazepril or other ACE inhibitors. Cross-reactivity can occur between different ACE inhibitors, so dogs that have experienced adverse reactions to medications such as enalapril, lisinopril, or ramipril may also react to benazepril. Signs of previous allergic reactions may have included facial swelling, hives, difficulty breathing, or sudden collapse. Any history of adverse reactions to cardiovascular medications should be disclosed to the veterinarian before starting benazepril therapy.

Dogs with clinically significant hypotension should not receive benazepril, as further blood pressure reduction could cause dangerous cardiovascular compromise. Hypotension may be present in dogs with severe dehydration, shock, or advanced heart failure with poor cardiac output. In these situations, stabilization of the patient's condition is necessary before ACE inhibitor therapy can be safely initiated. Veterinarians typically assess blood pressure and overall hemodynamic status before prescribing benazepril to ensure the patient can tolerate the medication's blood pressure-lowering effects.

Significant bilateral renal artery stenosis is a contraindication to ACE inhibitor therapy, though this condition is rare in dogs. In patients with severely compromised blood flow to the kidneys, ACE inhibitors can precipitate acute kidney failure by further reducing renal perfusion pressure. Dogs with known or suspected renovascular disease require careful evaluation before receiving benazepril. Severe pre-existing kidney failure with minimal remaining function may also preclude ACE inhibitor use, though benazepril can often be used cautiously in dogs with moderate kidney disease under close monitoring.

Pregnancy and lactation represent relative contraindications to benazepril use. ACE inhibitors can cause fetal developmental abnormalities and are not recommended for use in pregnant dogs. Lactating dogs should also avoid benazepril, as the medication can pass into milk and affect nursing puppies. Female dogs of breeding age should not receive benazepril if pregnancy is planned or possible. Dogs with significant hyperkalemia should not receive benazepril until potassium levels are corrected, as ACE inhibitors can further elevate potassium levels through aldosterone suppression. Complete disclosure of the dog's health history, including all medications and concurrent conditions, enables the veterinarian to determine whether benazepril is appropriate and safe.

Informing your veterinarian about all medications, supplements, and treatments your dog is currently receiving is essential before starting benazepril, as several clinically significant drug interactions can occur. ACE inhibitors interact with various medication classes, and comprehensive medication history allows the veterinarian to identify potential concerns, adjust doses as needed, or select alternative treatments. This includes prescription medications, over-the-counter products, supplements, and any other substances the dog receives regularly.

Benazepril interacts with diuretics, which are commonly prescribed alongside ACE inhibitors for heart failure management. The combination is often therapeutically beneficial, but careful dose adjustment is necessary, particularly when initiating treatment. Diuretics such as furosemide can cause volume depletion, which may enhance the blood pressure-lowering effects of benazepril and increase the risk of hypotension or acute kidney injury. Veterinarians typically start benazepril at lower doses when adding it to existing diuretic therapy and monitor closely for adverse effects. Potassium-sparing diuretics like spironolactone require particular attention, as the combination with ACE inhibitors increases the risk of hyperkalemia.

Nonsteroidal anti-inflammatory drugs (NSAIDs) can significantly interact with benazepril, potentially reducing the medication's effectiveness and increasing the risk of kidney damage. NSAIDs block prostaglandins that help maintain kidney blood flow, and when combined with ACE inhibitors that also affect renal hemodynamics, the risk of acute kidney injury increases substantially. Common veterinary NSAIDs include carprofen, meloxicam, and deracoxib. If pain management is needed in dogs receiving benazepril, veterinarians may recommend alternative analgesics or carefully monitor kidney function when short-term NSAID use is necessary.

Potassium supplements and potassium-rich dietary additions can interact with benazepril, potentially causing dangerous hyperkalemia. ACE inhibitors reduce aldosterone secretion, which normally promotes potassium excretion by the kidneys. When potassium intake is supplemented in dogs receiving ACE inhibitors, potassium levels can rise to dangerous levels. Pet owners should inform the veterinarian about any supplements their dog receives, including potassium-containing products or electrolyte supplements. Regular monitoring of serum potassium levels helps prevent this complication. Other antihypertensive medications, including calcium channel blockers and beta-blockers, may have additive blood pressure-lowering effects when combined with benazepril, requiring dose adjustments and careful monitoring.

Several important precautions should be observed when using benazepril to ensure safe and effective treatment of cardiovascular or kidney disease in dogs. Baseline laboratory evaluation including kidney function tests, electrolytes, and complete blood count is recommended before initiating therapy, as these values help guide dosing decisions and provide reference points for monitoring. Dogs with pre-existing kidney dysfunction require particularly careful evaluation to determine whether ACE inhibitor therapy is appropriate and what starting dose is safest. Accurate weight measurement ensures proper dosing, which is especially important with medications that affect blood pressure.

Hydration status must be assessed and maintained during benazepril therapy. Dehydrated dogs are at significantly increased risk of hypotension and acute kidney injury when receiving ACE inhibitors. Dogs should have free access to fresh water at all times, and any conditions causing fluid loss such as vomiting, diarrhea, or excessive panting should be promptly addressed. During hot weather or periods of increased activity, extra attention to hydration is warranted. Pet owners should contact the veterinarian if their dog stops eating or drinking, develops vomiting or diarrhea, or shows signs of dehydration.

Regular monitoring during treatment is essential for dogs receiving benazepril. Follow-up blood work is typically recommended within one to two weeks of starting therapy to assess kidney function and electrolyte levels. Ongoing monitoring at intervals determined by the veterinarian, often every three to six months for stable patients, helps track disease progression and medication effects. More frequent monitoring may be needed during dose adjustments, if the dog's condition changes, or if other medications are added or modified. Blood pressure monitoring may also be performed periodically to assess treatment efficacy.

Anesthetic considerations are important for dogs receiving benazepril who require sedation or general anesthesia for procedures. ACE inhibitors can enhance the hypotensive effects of anesthetic agents, and veterinarians may recommend withholding benazepril on the morning of procedures or taking special precautions during anesthesia. Pet owners should always inform any veterinarian providing care that their dog is receiving benazepril.

Special populations require additional precautions. Geriatric dogs, who are the most common recipients of benazepril due to age-related cardiac and kidney disease, may be more sensitive to the medication's effects and may require lower starting doses. Dogs with severe heart failure may have altered drug distribution and elimination. Patients with both heart disease and kidney disease require careful balancing of treatment goals. Any changes in the dog's health status, activity level, appetite, or behavior should be reported to the veterinarian, as these may indicate disease progression or medication-related effects requiring attention.

Proper storage of benazepril tablets maintains medication potency and ensures consistent therapeutic effects throughout the treatment period. The tablets should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit, with protection from excessive heat, moisture, and light. Avoid storing the medication in bathrooms, which tend to be humid, or in vehicles or near windows where temperature fluctuations and light exposure occur. A cool, dry medicine cabinet or drawer away from heat sources provides an ideal storage environment for maintaining tablet stability.

Benazepril tablets should remain in their original container with the child-resistant cap secured between uses. The manufacturer's packaging is designed to protect the medication from environmental factors that could affect potency. If the medication is dispensed by the pharmacy in a different container, ensure it is tightly closed after each use. Before administering each dose, verify the expiration date on the container and do not use tablets that have expired, as potency cannot be guaranteed. Tablets that appear discolored, crumbling, or have an unusual odor should not be used and should be returned to the pharmacy for inspection and replacement.

Safe handling and disposal practices protect household members and the environment. Benazepril tablets should be kept in a secure location inaccessible to children and pets. While the medication is not typically palatable, accidental ingestion could occur, particularly in curious children or dogs that may eat dropped tablets. Pet owners should wash their hands after handling the medication, especially before eating or touching their face. Pregnant women should avoid handling benazepril tablets due to the medication's potential effects on fetal development. Unused or expired medication should be disposed of properly through pharmacy take-back programs or following FDA guidelines for safe medication disposal rather than flushing or discarding in regular household trash where environmental contamination or access by others could occur.

Benazepril is used across all dog breeds for the management of heart disease and kidney disease, with no breed-specific contraindications to the medication itself. However, certain breeds have increased prevalence of conditions that may require benazepril therapy, making awareness of breed predispositions valuable for both veterinarians and pet owners. Understanding which breeds are at higher risk for cardiac and renal disease can prompt earlier screening and intervention, potentially improving outcomes with medications like benazepril.

Small and toy breeds are predisposed to degenerative mitral valve disease, the most common form of heart disease in dogs. Cavalier King Charles Spaniels have particularly high rates, often developing valve changes at young ages. Chihuahuas, Miniature Poodles, Dachshunds, Miniature Schnauzers, and similar small breeds also have elevated risk. These breeds often require benazepril as part of their heart disease management, sometimes for extended periods as the disease progresses slowly over years. Regular cardiac monitoring in predisposed breeds allows early detection and timely initiation of treatment.

Large and giant breeds are predisposed to dilated cardiomyopathy, a serious condition affecting the heart muscle. Doberman Pinschers have exceptionally high rates of DCM, often with rapid progression to heart failure. Great Danes, Irish Wolfhounds, Boxers, and Newfoundlands also have increased prevalence. Benazepril is commonly part of the treatment protocol for dilated cardiomyopathy in these breeds. Screening programs using echocardiography and biomarker testing can identify affected dogs before clinical signs develop, allowing earlier treatment initiation.

Breed predispositions to kidney disease also influence benazepril use. English Cocker Spaniels, Bull Terriers, Samoyeds, and Bernese Mountain Dogs have hereditary forms of kidney disease that may benefit from ACE inhibitor therapy. Shar-Peis are prone to renal amyloidosis. Any breed can develop kidney disease with age, and benazepril may be prescribed for proteinuric kidney disease regardless of breed. Giant breeds and large breeds may require higher total doses of benazepril due to their size, while toy breeds require careful calculation to avoid overdosing. Senior dogs of all breeds commonly receive benazepril as they develop age-related cardiac or renal conditions. The veterinarian considers breed background along with individual patient factors when prescribing and monitoring benazepril therapy.

Several other ACE inhibitors are used in veterinary medicine, providing alternatives when benazepril is not the best choice for a particular patient. Enalapril, marketed as Enacard, was one of the first ACE inhibitors used in veterinary cardiology and remains widely prescribed. It requires conversion to its active form in the liver and is dosed twice daily for most cardiac indications. Lisinopril is a long-acting ACE inhibitor that does not require hepatic activation, potentially offering advantages in dogs with liver dysfunction. Ramipril is approved for veterinary use in some countries. The choice among ACE inhibitors depends on factors including the specific condition being treated, dosing convenience, patient tolerance, and veterinarian experience with different agents.

Heart failure management often involves multiple medications working together, with benazepril being one component of a comprehensive treatment protocol. Pimobendan is an inodilator medication that improves heart contractility and dilates blood vessels, often used alongside ACE inhibitors for advanced heart disease. Furosemide and other diuretics help control fluid accumulation associated with heart failure. Spironolactone, while also a diuretic, is valued for its aldosterone-blocking effects that may slow cardiac remodeling. Digoxin may be added for certain rhythm disturbances or to support cardiac function. The combination of these medications is tailored to each patient's specific needs and disease stage.

For dogs with kidney disease being treated with benazepril, complementary therapies support overall kidney health and management. Phosphate binders help control elevated phosphorus levels common in kidney disease. Omega-3 fatty acid supplements may provide anti-inflammatory benefits. Prescription kidney diets are formulated with appropriate protein, phosphorus, and sodium levels to reduce kidney workload. Anti-nausea medications and appetite stimulants may be needed as kidney disease progresses. Blood pressure monitoring and management with additional antihypertensive agents may be necessary. Subcutaneous fluid administration at home can help maintain hydration in dogs with significant kidney compromise. The veterinarian coordinates all aspects of kidney disease management, with benazepril serving as one important element of comprehensive care. Substitution of any cardiac or kidney medication should only be made under direct veterinary guidance, as these conditions require careful ongoing management.